For more than a century, scientists pursued a cancer vaccine that could train the body to fight its own disease and succeed in late-stage trials. For decades, results fell short. All of that changed last month when Moderna and Merck announced that their personalized mRNA vaccine, intismeran autogene, succeeded in a Phase 3 melanoma trial, a historic first.
This isn't as simple as getting a shot. First, patients underwent surgery to remove all visible primary tumors and any affected lymph nodes. More than just removing primary tumors, this provided the researchers with tissue samples that could be used to create an individualized vaccine.
After surgery, patients received Keytruda (pembrolizumab), an immunotherapy that releases the brakes on the immune system, and Intismeran, the custom mRNA vaccine tailored to each patient’s tumor mutations that was being researched.
Compared to Keytruda alone, the combination significantly lowered the risk of recurrence (technically called "recurrence-free survival") and spread to distant organs (distant metastasis-free survival). Five-year data from Phase 2b showed a 49% reduction in recurrence or death and a 59% reduction in distant spread or death versus Keytruda alone.
So, why is it working this time?
Most past cancer vaccines targeted one or two shared proteins many tumors might have.
Smart in theory, but slippery in practice. Tumors evolve, hide those targets, or never show them strongly enough for the antibodies to find them.
But, Intismeran makes it personal.
After surgery, the DNA of the tumor is sequenced to find mutations unique to each patient’s cancer. An algorithm then selects the most promising mutation-derived targets, known as neoantigens. A custom mRNA vaccine is created to encode up to 34 of these patient-specific neoantigens. The vaccine trains the body's T cells (white blood cells) to recognize the mutant “fingerprints,” while Keytruda removes immune “brakes” so the T cells can do their job. As Merck’s Dean Li put it, Keytruda “unlocks the dogs of war,” and the vaccine gives those dogs your cancer’s scent.
mRNA vaccines don’t contain a virus or live cells. They carry instructions for your own cells to briefly make specific protein fragments (neoantigens) that look like pieces of the tumor. Your immune system sees these, learns to recognize them, and then hunts down any cells displaying the same fragments—ideally, the remaining cancer cells.
Melanoma is a strong test case because it tends to carry many mutations, providing more unique targets, or "shots on goal," for the immune system.
For patients, this treatment is adjuvant (or secondary) therapy, given after surgery to lower the chance that melanoma returns or spreads. Full data details are still being prepared for medical meetings and regulatory review, and the companies plan to file for approval as soon as next year.
That brings us to the trillion dollar question: will this approach will work as well in cancers with fewer mutations, like lung, kidney, or pancreatic cancers. We'll know soon enough as trials are already underway.
You don’t need to be a scientist to feel the shift.
This is prevention-adjacent care that relies on your body’s own defenses, tuned to your biology. This is a medical advance that complements what already works: early detection, surgical removal when possible, and immune-supportive care under a doctor’s guidance.
This isn't the end of cancer, but it is hard to overstate the value of this leap. Personalized medicine designed exclusively for one person's specific illness. If regulators approve it, melanoma will be the first, but it won't be the last life-ending illness to meet its (genetic) match.
Sources:
https://en.wikipedia.org/wiki/Intismeran_autogene
https://en.wikipedia.org/wiki/Pembrolizumab
https://pmc.ncbi.nlm.nih.gov/articles/PMC13064569/
https://www.sciencedirect.com/topics/immunology-and-microbiology/neoantigen
